UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2024

SPRINGWORKS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39044
(Commission
File Number)

83-4066827
(I.R.S. Employer
Identification No.)

100 Washington Blvd Stamford, CT
(Address of principal executive offices)

Not Applicable
(Former name or former address, if changed since last report.)

Registrant’s telephone number, including area code: (203) 883-9490

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, par value $0.0001 per share</td>
<td>SWTX</td>
<td>The Nasdaq Global Select Market</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 16, 2024, SpringWorks Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders to consider and vote on the proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 5, 2024. The final voting results are set forth below.

Proposal 1 - Election of Directors
The stockholders elected the person named below to serve as a Class II director of the Company for a three-year term that expires at the Company’s annual meeting of stockholders in 2027 and until her successor has been duly elected and qualified, subject to her earlier death, resignation or removal. The results of such vote were as follows:

<table>
<thead>
<tr>
<th>Director Name</th>
<th>Votes For</th>
<th>Withheld</th>
<th>Abstentions/Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freda Lewis-Hall</td>
<td>50,328,375</td>
<td>15,800,834</td>
<td>3,372,116</td>
</tr>
</tbody>
</table>

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm
The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of such vote were as follows:

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Abstentions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>69,485,322</td>
<td>5,709</td>
<td>10,294</td>
</tr>
</tbody>
</table>

Proposal 3 - Non-Binding Advisory Vote on Executive Compensation
The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the annual meeting of stockholders. The results of such vote were as follows:

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Abstentions/Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>38,332,463</td>
<td>27,761,536</td>
<td>3,407,326</td>
</tr>
</tbody>
</table>
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SpringWorks Therapeutics, Inc.

Date: May 17, 2024

By: /s/ Francis I. Perier, Jr.

Francis I. Perier, Jr.
Chief Financial Officer